



Pharmaceutical Approach to COVID-19

Katie Kohn

COVID-19 Structure and Binding Process









Challenges of Treating COVID-19



- No known antiviral treatment or vaccine
- Asymptomatic carriers
- Incubation period
- Variability of antibodies

Potential Antiviral Treatments Under Investigation


	Structure	Target	Current Application
Remdesivir	 <p>Remdesivir</p>	Transcription	Ebola
Favipiravir (Avigan)	 <p>Favipiravir</p>	Transcription	Influenza
Oseltamivir (Tamiflu)	 <p>Oseltamivir</p>	Neuraminidase	Influenza A & B
Ribavirin	 <p>Ribavirin</p>	Transcription	Hepatitis C
Lopinavir/Ritonavir	 <p>Lopinavir Ritonavir</p>	Protease	HIV
Umivenofir (Arbidol)		Fusion	Influenza

Other Potential Treatments





- Hydroxychloroquine, chloroquine, azithromycin
 - EUA issued and retracted due to severe side effects and ineffectiveness
- Corticosteroids
 - Clinical recommendations shift toward usage for critically ill
- Convalescent plasma
 - EUA issued, questionable scientific basis



Status of COVID Vaccine Development



Comparison of Leading Vaccine Candidates

	Moderna	Pfizer	AZN/Oxford	Merck/IAVI
Method				
Technology	mRNA nanoparticle	mRNA nanoparticle	Non-replicating viral vector (Chimpanzee Adenovirus)	Recombinant Vesicular Stomatitis Virus (rVSV)
Antigen	Modified full-length s protein	Full-length s protein	Full-length s protein	S protein

Complexities With Vaccine Deployment

- From 2010 to 2015, vaccines prevented an estimated 10 million deaths (WHO)
- Factors such as dosage, frequency and subpopulation effects must be evaluated
- Premature deployment presents safety risks
 - Polio (1955) to Dengue (2017)
- Politics, distrust, and misinformation effect inoculation rates and success



Questions?
